Human Microbiome Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Human Microbiome Market is segmented by Application (Therapeutics and Diagnostics), Disease (Obesity, Diabetes, Autoimmune Disorder, Cancer, Gastrointestinal Disorders, Central Nervous System Disorders, and Other Diseases), Product (Probiotics, Prebiotics, Symbiotic, and Other Products), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The Market Size and Forecasts are Provided in Terms of Value (USD Billion) for all the Above Segments in this Industry Report.

Human Microbiome Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Human Microbiome Market Size

Human Microbiome Market Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Market Size (2025) USD 1.05 Billion
Market Size (2030) USD 2.24 Billion
CAGR (2025 - 2030) 16.37 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Human Microbiome Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Human Microbiome Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Human Microbiome Market Analysis

The Human Microbiome Market size is estimated at USD 1.05 billion in 2025, and is expected to reach USD 2.24 billion by 2030, at a CAGR of 16.37% during the forecast period (2025-2030). The increasing need for human microbiome therapeutics to treat various conditions such as diabetes, asthma, metabolic disorders, and others and the widespread occurrence of lifestyle-related diseases is likely to drive significant demand for these products, resulting in market growth throughout the forecast period.

For instance, a study published by the Institute for Health Metrics and Evaluation in June 2023 reported that the global diabetic patient population is expected to reach 1.3 billion by 2050. In addition, the data published by the Global Initiative For Asthma Organization in May 2024 reported that asthma ranks among the most prevalent chronic non-communicable diseases, impacting more than 260 million individuals globally each year. Thus, the growing burden of lifestyle-related disorders is likely to drive the demands for human microbiome therapeutics, hence contributing to the market growth.


The human microbiome gained attention due to its links to various respiratory diseases and immune function. This led to increased clinical research activities, thus contributing to the market growth. For instance, in September 2024, researchers from the Nuffield Department of Medicine identified a connection between certain potentially harmful bacteria and airway inflammation in individuals suffering from severe asthma. The team observed that healthy individuals and those with mild asthma microbiomes exhibited comparable microbial diversity. However, in individuals with severe asthma, 23% of the microbiomes were predominantly influenced by one of three respiratory pathogens: Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae.


Additionally, a study published in the Journal of Cell in August 2024 involved a group of researchers from the Netherlands who examined nasopharyngeal, oropharyngeal, and saliva samples from different age groups and investigated the microbial composition of these samples to explore the relationship between the microbiota in the upper respiratory tract. Research indicated that the upper respiratory tract microbiome is closely connected to respiratory health and significantly influences susceptibility to respiratory infections. Thus, such studies indicate the relationship between human microbiome and respiratory diseases, creating more opportunities for market players to develop products, thus contributing to market growth.


The above-mentioned factors, such as the increasing prevalence of lifestyle-related diseases and rising clinical research studies, are anticipated to drive the demand for human microbiomes and contribute to the market's growth. However, a lack of comprehensive research and stringent government regulations may hinder the market growth over the forecast period.

Human Microbiome Industry Overview

The market for human microbiome is semi-consolidated, and several players are coming up with new products. Some of the key players in the human microbiome market are AOBiome, ResBiotic Nutition Inc., Axial Biotherapeutics Inc., International Flavors & Fragrances Inc., Enterome, Evelo Biosciences Inc., Finch Therapeutics Group Inc., Microba, Exeliom Biosciences SAS, Osel Inc., Second Genome Inc. and Seres Therapeutics, among others. The market exhibits moderate competitiveness, with various companies introducing innovative products.


Companies hold significant market shares and focus on prioritizing improving their therapeutics pipeline by creating effective and safe medications. For instance, in October 2024, AOBiome Therapeutics, Inc. received a patent grant from the United States Patent Office (USPTO) for the composition of matter. This patent covered claims about its exclusive strain of beneficial ammonia-oxidizing bacteria (AOB), classified as Nitrosomonas eutropha. The company’s clinical candidate B244 has shown effectiveness in treating several conditions, including mild-to-moderate atopic dermatitis (eczema) along with associated moderate-to-severe pruritus (itch) and mild-to-moderate acne vulgaris (acne).


Thus, the regulatory approvals and patent filings for innovations in products are likely to drive market growth.

Human Microbiome Market Leaders

  1. Second Genome Inc

  2. Seres Therapeutics

  3. Axial Biotherapeutics Inc

  4. DuPont

  5. Synthetic Biologics.

  6. *Disclaimer: Major Players sorted in no particular order
Human Microbiome Market Competitive Landscape
Need More Details on Market Players and Competiters?
Download PDF

Human Microbiome Market News

  • November 2024: MicrobioTx, based in Bangalore, launched a new gut health test that analyzes the gut microbiome through a simple finger-prick blood sample in India. This advancement allows for gut microbiome profiling with just a finger-prick, which previously could only be done using stool samples, thus eliminating the need for stool collection.
  • September 2024: Microbiome company Seed entered the physical retail space for the first time through an exclusive partnership with Target. Target will offer Seed’s products both in-store and online, featuring the DS-01 Daily Synbiotic, PDS-08 Pediatric Daily Synbiotic, and a new exclusive item, the DS-01 14 Day Daily Gut Reset.
  • September 2024: Floré introduced its latest line of probiotics specifically created to support neurodiversity. The new offerings, Pathways Support and Mood Support, have beneficial effects of customized probiotic supplementation for individuals with autism spectrum disorder (ASD). Each product contains 30 capsules and can be purchased as a one-time order or through a monthly subscription.
  • April 2024: Seres Therapeutics, Inc. mentioned that enrolment has been completed for the placebo-controlled cohort-2 of its Phase-1b trial evaluating SER-155 in patients who have undergone allogeneic hematopoietic stem cell transplantation (Allo HSCT). SER-155 is an orally taken consortium of bacteria, developed from cell banks to decrease the occurrence and severity of infections originating from the digestive tract, as well as related bloodstream infections, including those potentially resistant to antibiotics.

Human Microbiome Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence of Lifestyle-related Diseases
    • 4.2.2 Growing Geriatric Population
  • 4.3 Market Restraints
    • 4.3.1 Lack of Comprehensive Research
    • 4.3.2 Stringent Government Regulations
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value in USD Billion)

  • 5.1 Therapeutics
    • 5.1.1 Diagnostics
  • 5.2 By Disease
    • 5.2.1 Obesity
    • 5.2.2 Diabetes
    • 5.2.3 Autoimmune Disorders
    • 5.2.4 Cancer
    • 5.2.5 Gastrointestinal Disorders
    • 5.2.6 Central Nervous System Disorders
    • 5.2.7 Other Diseases
  • 5.3 By Product
    • 5.3.1 Probiotics
    • 5.3.2 Prebiotics
    • 5.3.3 Symbiotics
    • 5.3.4 Other Products
  • 5.4 By Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Aobiome
    • 6.1.2 Resbiotic Nutition Inc.
    • 6.1.3 Axial Biotherapeutics Inc.
    • 6.1.4 International Flavors & Fragrances Inc.
    • 6.1.5 Enterome
    • 6.1.6 Evelo Biosciences Inc.
    • 6.1.7 Finch Therapeutics Group Inc.
    • 6.1.8 Microba
    • 6.1.9 Exeliom Biosciences SAS
    • 6.1.10 Osel Inc.
    • 6.1.11 Second Genome Inc.
    • 6.1.12 Seres Therapeutics
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Human Microbiome Industry Segmentation

As per the scope of the report, the human microbiome is a full array of microorganisms (the microbiota) that live in humans. More specifically, the collection of microbial genomes that contribute to a human's broader genetic portrait, or metagenome.


The human microbiome market is segmented by application, disease, and product. By applications, the market is segmented into therapeutics and diagnostics. By disease, the market is segmented into obesity, diabetes, autoimmune disorders, cancer, gastrointestinal disorders, central nervous system disorders, and other diseases. By products, the market is segmented into probiotics, prebiotics, symbiotics and other products. By geography, the global market is segmented into North America (United States, Canada, Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, Rest of Middle East and Africa), and South America (Brazil, Argentina, Rest of South America). The market report also covers the estimated human microbiome market size and market trends for 17 countries across major regions globally. The report offers the value (in USD billion) for the above segments.

Therapeutics Diagnostics
By Disease Obesity
Diabetes
Autoimmune Disorders
Cancer
Gastrointestinal Disorders
Central Nervous System Disorders
Other Diseases
By Product Probiotics
Prebiotics
Symbiotics
Other Products
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Human Microbiome Market Research FAQs

What is the market size of human microbiome?

The human microbiome market size is expected to reach USD 1.05 billion in 2025 and grow at a CAGR of 16.37% to reach USD 2.24 billion by 2030.

What is the market outlook for Probiotics? 

The probiotics market is witnessing considerable expansion and is expected to maintain positive growth in the future due to the rising awareness of gut health, increasing demand for functional foods and beverages, and significant applications in skin health, oral care, and weight management.

What are the challenges in microbiome therapeutics? 

Microbiome therapeutics, which aim to alter the human microbiome to address diseases, encounter a range of substantial challenges comprising scientific, regulatory, manufacturing, and clinical aspects.

What is the microbiome therapeutics market? 

The microbiome therapeutics market is an emerging and rapidly evolving field of biotechnology that aims to utilize microbiome-based treatments to address various health issues by reestablishing microbial equilibrium in the body.

Are Microbiome tests FDA approved?

Most microbiome tests available on the market, especially those aimed at general wellness or consumer insights (such as dietary guidance or gut health profiling), lack FDA approval. These tests are usually promoted as direct-to-consumer (DTC) offerings and categorized as general wellness products, exempting them from the need for FDA approval since they do not assert the ability to diagnose, treat, or prevent diseases.